Disclosed is an antibody which binds to human CC chemokine receptor 4 (CCR4) and which is capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4, and which comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein the CDRs are as disclosed in the complete specification. Also disclosed is the use of said antibody in the manufacture of a medicament for the treatment or diagnosis of a condition associated with increased CCR4 expression or activity.
